Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities

Oxford Biomedica

Oxford Biomedica has acquired Oxxon Therapeutics, the Oxford-based therapeutic vaccines company, for £16m.

Oxford Biomedica is planning to raise up to £30m in a share offer in order to fund international expansion and clinical trials for new gene therapy-based products.

Oxford Biomedica is seeking a partner to fund the development of its TroVax cancer vaccine, and is also planning to seek a listing on London's main market.

Oxford Biomedica has raised £8.5m in a share placing in order to set up a new gene division, and the proceeds will be spent on the recruitment of scientists and the marketing of two new technologies.

Oxford Biomedica has raised a further £5m in a share issue for the development of gene therapy, and is looking to move from the Alternative Investment Market to a full stockmarket listing.

Oxford Biomedica, the gene-therapy concern, is planning a public share offer in November in order to raise £5m for the funding of a lease on a site in Oxford and the recruitment of up to 30 staff.